If you’ve ever sat through a tumor board, you know the bottleneck is almost never the drug. It’s the staining.
Every time a pathologist needs to confirm a biomarker – HER2, PD-L1, Ki-67, you name it – the slide gets sent back for another round of immunohistochemistry.
Each round costs:
tissue (of which there’s never enough),
time (of which there’s less), and
money (of which the hospital has even less).
ViewsML, a Vancouver-based AI diagnostics company, thinks the answer is to stop staining the slide at all. Instead, use AI to predict what the IHC stain would look like from a standard H&E image.
They just closed a $4.9M oversubscribed seed to push that idea toward commercialization.
ViewsML seed — $4.9M oversubscribed
Lead
Wittington Ventures
New
Mayo Clinic
New
Continuum Health
Repeat
Debiopharm
Repeat
RiSC Capital
Repeat
WUTIF, Defined, e-Fund
Strategic drug developer plus a major academic health system signing in at seed.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you, contextualized and written directly to you, so you cut through the noise and immediately understand why it matters.
The lead investor is Wittington Ventures. Continuum Health Ventures also joined as new. Repeats came from RiSC Capital, Debiopharm, WUTIF, Defined, and e-Fund.
We also saw Mayo Clinic come in as a new investor, which, I think, is the part that matters. It’s usually pretty weird to see an academic health systems writing checks to private biotech. It usually means there’s a real interest in deploying the thing internally.
The Debiopharm participation is its own signal.
Debiopharm is a Swiss drug developer, not a generalist health-tech investor. If they’re putting money in again, it’s because ViewsML has something useful for their clinical biomarker workflows, which is a specific use case and not a vibes check.
Virtual staining isn’t entirely a new idea. Paige, PathAI, Owkin, and Aignostics have all been working in computational pathology, with various AI-on-pathology products and partnerships. What ViewsML seems to be arguing is that they can virtualize multiple biomarkers from a single slide, which is a harder problem and a more useful one.
The market these companies are chasing is big, and the AI-in-biotech trend is real. We’ve been tracking it in pharma partnerships, in antibody design, and in molecular glue discovery. Pathology is the quietest of these fronts, but it’s the one most likely to show up in your doctor’s workflow first.
$4.9M is a small round, but the investor mix is the real tell.
Something useful is probably getting built.
